MedTrace Logo

Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes

NCT06931275 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1178

Last updated 2025-04-17

No results posted yet for this study

Summary

The overall goal of the study is to create a standardized, stakeholder-informed system within EMRs, that will enable an equitable and regular prescription and documentation of advanced diabetes technologies. This will reduce racial disparities and generate an understanding of the reasons behind prescription decisions.

The study will highlight the development and implementation an EMR-based Best Practice Advisory (BPA).

The study will answer whether the EMR-based BPA can effectively reduce disparities. Additionally, it will explore why providers may not prescribe advanced diabetes technologies.

Patients will also be surveyed to understand their perspectives on developing the EMR-based BPA.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

OTHER

EMR-based BPA model

Advanced Diabetes Technologies including AIDs, insulin pumps and CGMs will be prescribed to patients after an EMR-based BPA implementation at six centers.

BEHAVIORAL

Placebo (EMR-based without BPA model)

Advanced Diabetes Technologies including AIDs, insulin pumps and CGMs will be prescribed to patients after an EMR-based system without BPA at the implementation at six centers.

Sponsors & Collaborators

  • T1D Exchange, United States

    lead OTHER

Principal Investigators

  • Osagie Ebekozien · T1DExchange

  • Nestoras Mathioudakis · Johns Hopkins University

  • Risa Wolf · Johns Hopkins Pediatrics

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-13
Primary Completion
2027-07-30
Completion
2027-07-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06931275 on ClinicalTrials.gov